A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral IQ-007 in Healthy Male and Female Adult Participants
Latest Information Update: 01 Apr 2025
At a glance
- Drugs IQ 007 (Primary)
- Indications Epilepsy
- Focus Adverse reactions; Therapeutic Use
- Sponsors iQure Pharma
- 01 Apr 2025 New trial record